New developments in the staging of melanoma

Cancer Investigation

Volumn 23, Issue 6, 2005, Pages 561-567

  Baruch, Amy C ^a   Shi, Jiaqi ^b   Feng, Yongmei ^b   Nelson, Mark A ^a  

^a UNIVERSITY OF ARIZONA   (United States)

^b NONE

Author keywords

cDNA arrays; Melanoma; Molecular techniques; Proteomics; RT PCR

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 2; CADHERIN; CATHEPSIN D; CD146 ANTIGEN; CELL ADHESION MOLECULE; COMPLEMENTARY DNA; CYSTEINYLDOPA; EPHRIN RECEPTOR A2; FOCAL ADHESION KINASE; GAGE ANTIGEN; GLUTATHIONE TRANSFERASE; GUANINE NUCLEOTIDE BINDING PROTEIN; HEPATOMA DERIVED GROWTH FACTOR; LACTATE DEHYDROGENASE; MELAN A; MELANOMA ANTIGEN; MELANOMA ANTIGEN 3; MONOPHENOL MONOOXYGENASE; NUCLEOPHOSMIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN 14 3 3; PROTEIN P97; PROTEIN S100B; TUMOR ANTIGEN; TUMOR MARKER; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; BLOOD; BONE MARROW EXAMINATION; CANCER STAGING; DIAGNOSTIC ACCURACY; DNA MICROARRAY; GENE EXPRESSION; HUMAN; HUMAN GENOME; LYMPH NODE METASTASIS; MASS SPECTROMETRY; MELANOMA; MELANOMA CELL; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROGNOSIS; PROTEOMICS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SENTINEL LYMPH NODE;

HUMANS; MELANOMA; NEOPLASM STAGING; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROTEOMICS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SKIN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 26844484536     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.1080/07357900500202887     Document Type: Review

References (68)

1. Diepgen, T.L.; Mahler, V. The epidemiology of skin cancer. Br. J. Dermatol. 2002, 146, 1-6.
2. Rigel, D.S. The effect of sunscreen on melanoma risk. Dermatol. Clin. 2002, 20(4), 601-606.
3. Jemal, A.; Tiwari, R.C.; Murray, T.; Ghafoor, A.; Samuels, A.; et al. Cancer statistics, 2004. CA, Cancer J. Clin. 2004, 54 (1), 8-29.
4. Howe, H.L.; Wingo, P.A.; Thun, M.J.; Ries, L.A.; Rosenberg, H.M.; Feigal, E.G.; Edwards, B.K. Annual report to the nation on the status of cancer (1973 through 1998), featuring cancers with recent increasing trends. J. Natl. Cancer Inst. 2001, 93 (11), 824-842.
5. Breslow, A. Tumor thickness, level of invasion and node dissection in stage I cutaneous melanoma. Ann. Surg. 1975, 182 (5), 572-575.
6. Cochran, A.J. Prediction of outcome for patients with cutaneous melanoma. Pigment Cell Res. 1997, 10 (3), 162-167.
7. Reintgen, D.S.; Cox, E.B.; McCarty, K.S., Jr.; Vollmer, R.T.; Seigler, H.F. Efficacy of elective lymph node dissection in patients with intermediate thickness primary melanoma. Ann. Surg. 1983, 198 (3), 379-385.
8. Balch, C.M.; Buzaid, A.C.; Soong, S.J.; Atkins, M.B.; Cascinelli, N.; et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J. Clin. Oncol. 2001, 19 (16), 3635-3648.
9. Cabanas, R.M. An approach for the treatment of penile carcinoma. Cancer 1977, 39 (2), 456-466.
10. Reintgen, D.S.; Cox, C.; Slingluff, C.L., Jr.; Seigler, H.F. Recurrent malignant melanoma: the identification of prognostic factors to predict survival. Ann. Plast. Surg. 1992, 28 (1), 45-49.
11. Reintgen, D.; Cruse, C.W.; Wells, K.; Berman, C.; Fenske, N.; et al. The orderly progression of melanoma nodal metastases. Ann. Surg. 1994, 220 (6), 759-767.
12. Morton, D.L.; Thompson, J.F.; Essner, R.; Elashoff, R.; Stern, S.L.; et al. Validation of the accuracy of intraoperative lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma: a multicenter trial. Multicenter Selective Lymphadenectomy Trial Group. Ann. Surg. 1999, 230 (4), 453-463.
13. Thompson, J.F.; McCarthy, W.H.; Bosch, C.M.; O'Brien, C.J.; Quinn, M.J.; et al. Sentinel lymph node status as an indicator of the presence of metastatic melanoma in regional lymph nodes. Melanoma Res. 1995, 5 (4), 255-260.
14. Morton, D.L.; Wen, D.R.; Wong, J.H.; Economou, J.S.; Cagle, L.A.; et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch. Surg. 1992, 127 (4), 392-399.
15. Ross, M.I.; Reintgen, D.; Balch, C.M. Selective lymphadenectomy: emerging role for lymphatic mapping and sentinel node biopsy in the management of early stage melanoma. Sem. Surg. Oncol. 1993, 9 (3), 219-223.
16. Sung, J.; Li, W.; Shivers, S.; Reintgen, D. Molecular analysis in evaluating the sentinel node in malignant melanoma. Ann. Surg. Oncol. 2001, 8 (Suppl. 9), 29S-30S.
17. Cho, K.H.; Hashimoto, K.; Taniguchi, Y.; Pietruk, T.; Zarbo, R.J.; An, T. Immunohistochemical study of melanocytic nevus and malignant melanoma with monoclonal antibodies against S-100 subunits. Cancer 1990, 66(4), 765-771.
18. Yu, L.L.; Flotte, T.J.; Tanabe, K.K.; Gadd, M.A.; Cosimi, A.B.; et al. Detection of microscopic melanoma metastases in sentinel lymph nodes. Cancer 1999, 86 (4), 617-627.
19. Wang, X.; Heller, R.; VanVoorhis, N.; Cruse, C.W.; Glass, F.; et al. Detection of submicroscopic lymph node metastases with polymerase chain reaction in patients with malignant melanoma. Ann. Surg. 1994, 220 (6), 768-774.
20. Shivers, S.C.; Wang, X.; Li, W.; Joseph, E.; Messina, J.; et al. Molecular staging of malignant melanoma: correlation with clinical outcome. JAMA 1998, 280 (16), 1410-1415.
21. Bostick, P.J.; Morton, D.L.; Turner, R.R.; Huynh, K.T.; Wang, H.J.; et al. Prognostic significance of occult metastases detected by sentinel lymphadenectomy and reverse transcriptase-polymerase chain reaction in early-stage melanoma patients. J. Clin. Oncol. 1999, 17 (10), 3238-3244.
22. Lukowsky, A.; Bellmann, B.; Ringk, A.; Winter, H.; Audring, H.; Fenske, S.; Sterry, W. Detection of melanoma micrometastases in the sentinel lymph node and in nonsentinel nodes by tyrosinase polymerase chain reaction. J. Invest. Dermatol. 1999, 113 (4), 554-559.
23. Bieligk, S.C.; Ghossein, R.; Bhattacharya, S.; Coit, D.G. Detection of tyrosinase mRNA by reverse transcription-polymerase chain reaction in melanoma sentinel nodes. Ann. Surg. Oncol. 1999, 6 (3), 232-240.
24. Blaheta, H.J.; Ellwanger, U.; Schittek, B.; Sotlar, K.; MacZey, E.; et al. Examination of regional lymph nodes by sentinel node biopsy and molecular analysis provides new staging facilities in primary cutaneous melanoma. J. Invest. Dermatol. 2000, 114 (4), 637-642.
25. Li, W.; Stall, A.; Shivers, S.C.; Lin, J.; Haddad, F.; et al. Clinical relevance of molecular staging for melanoma: comparison of RT-PCR and immunohistochemistry staining in sentinel lymph nodes of patients with melanoma. Ann. Surg. 2000, 231 (6), 795-803.
26. Boi, S.; Cristofolini, P.; Togni, R.; Girlando, S.; Camerani, M.; et al. Detection of nodal micrometastases using immunohistochemistry and PCR in melanoma of the arm and trunk. Melanoma Res. 2002, 12 (2), 147-153.
27. Riccioni, L.; Farabegoli, P.; Nanni, O.; Morigi, F.; Polverelli, M.; et al. The sentinel lymph node in melanoma: utilization of molecular biology (RT-PCR) to detect occult metastases. Pathologica 2002, 94 (4), 190-195.
28. Carson, K.F.; Wen, D.R.; Li, P.X.; Lana, A.M.; Bailly, C.; Morton, D.L.; Cochran, A.J. Nodal nevi and cutaneous melanomas. Am. J. Surg. Pathol. 1996, 20 (7), 834-840.
29. Gutzmer, R.; Kaspari, M.; Brodersen, J.P.; Mommert, S.; Volker, B.; et al. Specificity of tyrosinase and HMB45 PCR in the detection of melanoma metastases in sentinel lymph node biopsies. Histopathology 2002, 41 (6), 510-518.
30. Russell-Jones, R. The value of reverse transcription-polymerase chain reaction in malignant melanoma. Br. J. Dermatol. 2001, 145 (2), 193-194.
31. Jung, F.A.; Buzaid, A.C.; Ross, M.I.; Woods, K.V.; et al. Evaluation of tyrosinase mRNA as a tumor marker in the blood of melanoma patients. J. Clin. Oncol. 1997, 15 (8), 2826-2831.
32. Kuo, C.T.; Hoon, D.S.; Takeuchi, H.; Turner, R.; Wang, H.J.; Morton, D.L.; Taback, B. Prediction of disease outcome in melanoma patients by molecular analysis of paraffin-embedded sentinel lymph nodes. J. Clin. Oncol. 2003, 21 (19), 3566-3572.
33. Takeuchi, H.; Taback, B.; Kuo, C.; Hoon, D.S. Clinicopathological utility of molecular staging for melanoma patients undergoing sentinel lymphadenectomy. Ann. Surg. Oncol. 2004, 11 (Suppl. 3), 152S-155S.
34. Morton, D.L.; Hoon, D.S.; Cochran, A.J.; Turner, R.R.; Essner, R.; et al. Lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma: therapeutic utility and implications of nodal microanatomy and molecular staging for improving the accuracy of detection of nodal micrometastases. Ann. Surg. 2003, 238 (4), 538-549.
35. Palmieri, G.; Ascierto, P.A.; Cossu, A.; Mozzillo, N.; Motti, M.L.; et al. Detection of occult melanoma cells in paraffin-embedded histologically negative sentinel lymph nodes using a reverse transcriptase polymerase chain reaction assay. J. Clin. Oncol. 2001, 19 (5), 1437-1443.
36. Smith, B.; Selby, P.; Southgate, J.; Pittman, K.; Bradley, C.; Blair, G.E. Detection of melanoma cells in peripheral blood by means of reverse transcriptase and polymerase chain reaction. Lancet 1991, 338 (8777), 1227-1229.
37. Brossart, P.; Keilholz, U.; Willhauck, M.; Scheibenbogen, C.; Mohler, T.; Hunstein, W. Hematogenous spread of malignant melanoma cells in different stages of disease. J. Invest. Dermatol. 1993, 101 (6), 887-889.
38. Stevens, G.L.; Scheer, W.D.; Levine, E.A. Detection of tyrosinase mRNA from the blood of melanoma patients. Cancer Epidemiol. Biomark. Prev. 1996, 5 (4), 293-296.
39. Battayani, Z.; Grob, J.J.; Xerri, L.; Noe, C.; Zarour, H.; et al. Polymerase chain reaction detection of circulating melanocytes as a prognostic marker in patients with melanoma. Arch. Dermatol. 1995, 131 (4), 443-447.
40. Proebstle, T.M.; Jiang, W.; Hogel, J.; Keilholz, U.; Weber, L.; Voit, C. Correlation of positive RT-PCR for tyrosinase in peripheral blood of malignant melanoma patients with clinical stage, survival and other risk factors. Br. J. Cancer 2000, 82 (1), 118-123.
41. Mellado, B.; Colomer, D.; Castel, T.; Munoz, M.; Carballo, E.; et al. Detection of circulating neoplastic cells by reverse-transcriptase polymerase chain reaction in malignant melanoma: association with clinical stage and prognosis. J. Clin. Oncol. 1996, 14 (7), 2091-2097.
42. Farthmann, B.; Eberle, J.; Krasagakis, K.; Gstottner, M.; Wang, N.; Bisson, S.; Orfanos, C.E. RT-PCR for tyrosinase-mRNA-positive cells in peripheral blood: evaluation strategy and correlation with known prognostic markers in 123 melanoma patients. J. Invest. Dermatol. 1998, 110(3), 263-267.
43. Ghossein, R.A.; Coit, D.; Brennan, M.; Zhang, Z.F.; Wang, Y.; et al. Prognostic significance of peripheral blood and bone marrow tyrosinase messenger RNA in malignant melanoma. Clin. Cancer Res. 1998, 4 (2), 419-428.
44. Szenajch, I.; Jasinski, B.; Synowiec, A.; Kulik, J.; Chomicka, M.; et al. Prognostic value of multiple reverse transcription-PCR tyrosinase testing for circulating neoplastic cells in malignant melanoma. Clin. Chem. 2003, 49 (9), 1450-1457.
45. Pittman, K.; Burchill, S.; Smith, B.; Southgate, I.; Joffe, J.; Gore, M.; Selby, P. Reverse transcriptase-polymerase chain reaction for expression of tyrosinase to identify malignant melanoma cells in peripheral blood. Ann. Oncol. 1996, 7 (3), 297-301.
46. Palmieri, G.; Pirastu, M.; Strazzullo, M.; Ascierto, P.A.; Satriano, S.M.; et al. Clinical significance of PCR-positive mRNA markers in peripheral blood and regional nodes of malignant melanoma patients. Melanoma Cooperative Group. Recent Results Cancer Res. 2001, 158, 200-203.
47. Blaheta, H.J.; Paul, T.; Sotlar, K.; Maczey, E.; Schittek, B.; et al. Detection of melanoma cells in sentinel lymph nodes, bone marrow and peripheral blood by a reverse transcription-polymerase chain reaction assay in patients with primary cutaneous melanoma: association with Breslow's tumour thickness. Br. J. Dermatol. 2001, 145 (2), 195-202.
48. Hoon, D.S.; Wang, Y.; Dale, P.S.; Conrad, A.J.; Schmid, P.; et al. Detection of occult melanoma cells in blood with a multiple-marker polymerase chain reaction assay. J. Clin. Oncol. 1995, 13 (8), 2109-2116.
49. Hoon, D.S.; Bostick, P.; Kuo, C.; Okamoto, T.; Wang, H.J.; Elashoff, R.; Morton, D.L. Molecular markers in blood as surrogate prognostic indicators of melanoma recurrence. Cancer Res. 2000, 60 (8), 2253-2257.
50. Palmieri, G.; Strazzullo, M.; Ascierto, P.A.; Satriano, S.M.; Daponte, A.; Castello, G. Polymerase chain reaction-based detection of circulating melanoma cells as an effective marker of tumor progression. Melanoma Cooperative Group. J. Clin. Oncol. 1999, 17 (1), 304-311.
51. Cheung, I.Y.; Cheung, N.K.; Ghossein, R.A.; Satagopan, J.M.; Bhattacharya, S.; Coit, D.G. Association between molecular detection of GAGE and survival in patients with malignant melanoma: a retrospective cohort study. Clin. Cancer Res. 1999, 5 (8), 2042-2047.
52. Banfalvi, T.; Boldizsar, M.; Gergye, M.; Gilde, K.; Kremmer, T.; Otto, S. Comparison of prognostic significance of serum 5-S-Cysteinyldopa, LDH and S-100B protein in stage III-IV malignant melanoma. Pathol. Oncol. Res. 2002, 8 (3), 183-187.
53. Takeuchi, H.; Kuo, C.; Morton, D.L.; Wang, H.J.; Hoon, D.S. Expression of differentiation melanoma-associated antigen genes is associated with favorable disease outcome in advanced-stage melanomas. Cancer Res. 2003, 63(2), 441-448.
54. Pacifico, M.D.; Grover, R.; Richman, P.; Daley, F.; Wilson, G.D. Validation of tissue microarray for the immunohistochemical profiling of melanoma. Melanoma Res. 2004, 14 (1), 39-42.
55. Camp, R.L.; Charette, L.A.; Rimm, D.L. Validation of tissue microarray technology in breast carcinoma. Lab. Invest. 2000, 80 (12), 1943-1949.
56. Hoos, A.; Urist, M.J.; Stojadinovic, A.; Mastorides, S.; Dudas, M.E.; et al. Validation of tissue microarrays for immunohistochemical profiling of cancer specimens using the example of human fibroblastic tumors. Am. J. Pathol. 2001, 158 (4), 1245-1251.
57. Berger, A.J.; Kluger, H.M.; Li, N.; Kielhorn, E.; Halaban, R.; Ronai, Z.; Rimm, D.L. Subcellular localization of activating transcription factor 2 in melanoma specimens predicts patient survival. Cancer Res. 2003, 63 (23), 8103-8107.
58. Korabiowska, M.; Bauer, H.; Quentin, T.; Stachura, J.; Cordon-Cardo, C.; Brinck, U. Application of new in situ hybridization probes for Ku70 and Ku80 in tissue microarrays of paraffin-embedded malignant melanomas: correlation with immunohistochemical analysis. Human Pathol. 2004, 35 (2), 210-216.
59. von Eggeling, F.; Davies, H.; Lomas, L.; Fiedler, W.; Junker, K.; Claussen, U.; Ernst, G. Tissue-specific microdissection coupled with ProteinChip array technologies: applications in cancer research. Biotechniques 2000, 29 (5), 1066-1070.
60. Bernard, K.; Litman, E.; Fitzpatrick, J.L.; Shellman, Y.G.; Argast, G.; et al. et al. Functional proteomic analysis of melanoma progression. Cancer Res. 2003, 63 (20), 6716-6725.
61. DeRisi, I.; Penland, L.; Brown, P.O.; Bittner, M.L.; Meltzer, P.S.; et al. Use of a cDNA microarray to analyse gene expression patterns in human cancer. Nat. Genet. 1996, 14 (4), 457-460.
62. Baldi, A.; Santini, D.; De Luca, A.; Paggi, M.G. cDNA array technology in melanoma: an overview. J. Cell. Physiol. 2003, 196 (2), 219-223.
63. Bittner, M.; Meltzer, P.; Chen, Y.; Jiang, Y.; Seftor, E.; et al. Molecular classification of cutaneous malignant melanoma by gene expression profiling. Nature 2000, 406 (6795), 536-540.
64. Seftor, E.A.; Meltzer, P.S.; Kirschmann, D.A.; Pe'er, J.; Maniotis, A.J.; et al. Molecular determinants of human uveal melanoma invasion and metastasis. Clin. Exp. Metastasis 2002, 19 (3), 233-246.
65. Kunz, M.; Koczan, D.; Ibrahim, S.M.; Gillitzer, R.; Gross, G.; Thiesen, H.J. Differential expression of thrombospondin 2 in primary and metastatic malignant melanoma. Acta Derm.-Venereol. 2002, 82 (3), 163-169.
66. Hoek, K.; Rimm, D.; Williams, K.; Zhao, H.; Ariyan, S.; et al. Expression profiling reveals novel pathways in the transformation of melanocytes to melanomas. Pigment Cell Res. 2004, 17 (4), 430.
67. Roesch, A.; Vogt, T.; Stolz, W.; Dugas, M.; Landthaler, M.; Becker, B. Discrimination between gene expression patterns in the invasive margin and the tumour core of malignant melanomas. Melanoma Res. 2003, 13 (5), 503-509.
68. McDonald, S.L.; Edington, H.D.; Kirkwood, J.M.; Becker, D. Expression analysis of genes identified by molecular profiling of VGP melanomas and MGP melanoma-positive lymph nodes. Cancer Biol. Ther. 2004, 5 (1), 110-120.